Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study *Phase 2 HexAgon data indicate INBRX-106 may substantially boost pembrolizumab efficacy, particularly in HPV-positive head and neck cancer.*